AI Article Synopsis
- The study summarizes the latest scientific findings on diagnosing, managing, and treating intrahepatic cholestasis in pregnancy.
- It emphasizes the importance of measuring postprandial serum bile acid levels to identify high-risk patients, particularly those with levels over 100 µmol/l in the third trimester.
- The first-line treatment, ursodeoxycholic acid, has been shown to have limited effectiveness in improving perinatal outcomes and may not alleviate itching, making its routine use controversial.
Article Abstract
Objective: The aim of this work is to summarize current scientific information focusing on the diagnosis, management, and treatment of intrahepatic cholestasis in pregnancy according to available literature.
Methodology: Literature sources were searched using the Web of Science, Scopus, and PubMed/Medline databases.
Conclusion: For the diagnosis and proper management of intrahepatic cholestasis of pregnancy, the postprandial serum bile acid value of the pregnant woman is crucial. Postprandial testing allows for a higher likelihood of identifying patients with significantly elevated bile acid levels. Bile acid values above 100 µmol/l, especially in the 3rd trimester, are associated with a significant risk of severe complications, particularly intrauterine fetal death. Ursodeoxycholic acid, the first-line treatment, according to available data, does not improve perinatal outcomes and has minimal effect on the sensation of itching in patients. The routine administration of ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy is controversial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.48095/cccg2024405 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!